Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

AUM Biosciences raises $27 million for cancer drugs

by Ryan Cross
October 15, 2021 | A version of this story appeared in Volume 99, Issue 38

 

AUM Biosciences has raised $27 million in series A funding to develop small-molecule therapies for genetically defined cancers. The Singapore-based start-up will use the funds to begin Phase 2 clinical trials of its lead programs: an inhibitor that targets the kinase MNK and a molecule that targets tumors that have TRK fusions. AUM is also developing a PI3K kinase inhibitor that it says could be useful in combating drug resistance in tumors.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.